Resisting resistance: Establishing new treatment options for CRPC patients

Shaunna Beedie, William D. Figg*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Overcoming drug resistance in castrate resistant prostate cancer requires improved understanding of mechanisms by which resistance occurs, as well as new treatment options. A recent study published in Nature (Li et al. 2015) examines the mechanism of abiraterone activity, and reveals the bioactivity of a breakdown product with exciting repercussions for therapy regimes.

Original languageEnglish
Pages (from-to)337-338
Number of pages2
JournalCancer Biology and Therapy
Issue number4
StatePublished - 2 Apr 2016
Externally publishedYes


  • abiraterone
  • enzalutamide
  • prostate cancer
  • ▵4-abiraterone


Dive into the research topics of 'Resisting resistance: Establishing new treatment options for CRPC patients'. Together they form a unique fingerprint.

Cite this